ReviewInternational journal of radiation oncology, biology, physics2016
Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Review in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- American Radium Society Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-Small Cell Lung Cancer Executive Summary.International journal of radiation oncology, biology, physics · 2025Guideline
- Clinical outcomes of image-guided proton therapy for histologically confirmed stage I non-small cell lung cancer.Radiation oncology (London, England) · 2018Trial
- Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.JAMA oncology · 2017Trial
- Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2017Trial
- Robustness of tumor control (TCP) and normal tissue complication probabilities (NTCP) for intensity modulated particle radiotherapy in locally advanced lung cancer: a scenario-based uncertainty analysis compared to photon radiotherapy (IMRT).Journal of thoracic disease · 2026Article
- Impact of ALC Nadir and EDRIC on survival outcomes in limited-stage small cell lung cancer receiving chemoradiotherapy: a retrospective analysis comparing twice-daily and once-daily radiotherapy.Frontiers in immunology · 2026Article
- Development and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies.BMC cancer · 2025Article
- Proton therapy achieves high-dose tumor control with organ preservation in complex metastatic adenoid cystic carcinoma: a case report of a refractory patient with 16 pulmonary metastases.Frontiers in oncology · 2025Article
- A dosimetric and robustness analysis of proton arc therapy with early energy layer and spot assignment for lung cancer versus conventional intensity modulated proton therapy.Acta oncologica (Stockholm, Sweden) · 2024Article
- On the Way to Accounting for Lung Modulation Effects in Particle Therapy of Lung Cancer Patients-A Review.Cancers · 2024Review
- Extending deterministic transport capabilities for very-high and ultra-high energy electron beams.Scientific reports · 2024Article
- A review of the clinical introduction of 4D particle therapy research concepts.Physics and imaging in radiation oncology · 2024Review
- Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.Frontiers in oncology · 2024Article
- Automatic lung segmentation of magnetic resonance images: A new approach applied to healthy volunteers undergoing enhanced Deep-Inspiration-Breath-Hold for motion-mitigated 4D proton therapy of lung tumors.Physics and imaging in radiation oncology · 2024Article
- Pulmonary function and toxicities of proton versus photon for limited-stage small cell lung cancer.Radiation oncology journal · 2023Article
- Detection of Early Myocardial Dysfunction by Imaging Biomarkers in Cancer Patients Undergoing Photon Beam vs. Proton Beam Radiotherapy: A Prospective Study.Journal of cardiovascular development and disease · 2023Article
- Surveying the clinical practice of treatment adaptation and motion management in particle therapy.Physics and imaging in radiation oncology · 2023Article
- Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.Cell communication and signaling : CCS · 2023Review
- Advances in treatment planning and management for the safety and accuracy of lung stereotactic body radiation therapy using proton pencil beam scanning: Simulation, planning, quality assurance, and delivery recommendations.Journal of radiosurgery and SBRT · 2023Article
- Stereotactic body proton therapy for non-small cell lung cancer: Clinical indications and recommendations.Journal of radiosurgery and SBRT · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 3 countries.
Funding
Abstract
Radiation dose escalation has been shown to improve local control and survival in patients with non-small cell lung cancer in some studies, but randomized data have not supported this premise, possibly owing to adverse effects. Because of the physical characteristics of the Bragg peak, proton therapy (PT) delivers minimal exit dose distal to the target volume, resulting in better sparing of normal tissues in comparison to photon-based radiation therapy. This is particularly important for lung cancer given the proximity of the lung, heart, esophagus, major airways, large blood vessels, and spinal cord. However, PT is associated with more uncertainty because of the finite range of the proton beam and motion for thoracic cancers. PT is more costly than traditional photon therapy but may reduce side effects and toxicity-related hospitalization, which has its own associated cost. The cost of PT is decreasing over time because of reduced prices for the building, machine, maintenance, and overhead, as well as newer, shorter treatment programs. PT is improving rapidly as more research is performed particularly with the implementation of 4-dimensional computed tomography-based motion management and intensity modulated PT. Given these controversies, there is much debate in the oncology community about which patients with lung cancer benefit significantly from PT. The Particle Therapy Co-operative Group (PTCOG) Thoracic Subcommittee task group intends to address the issues of PT indications, advantages and limitations, cost-effectiveness, technology improvement, clinical trials, and future research directions. This consensus report can be used to guide clinical practice and indications for PT, insurance approval, and clinical or translational research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.